SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PMTI FDA OK epilaser for some uses

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TerryJones101 who wrote (2)7/21/1996 10:17:00 AM
From: Jane Egan   of 20
 
The spinoff of Nexar would be to offer 25% of company and retain 75% by Palomar. This would be beneficial in that they could focus on their main objective, medical lasers. The issueing of additional shares is for continueing acquisitions and possibly a stock split. Your statement about speculation is true but I think that the third quarter will show whether they are going to meet their objectives. A profitable third quarter will give an indication of whether they can make the turn around in 1997. I am willing at this point to hold on to see if they can make their projections come true. Their earnings report in August (loss), again may hurt the stock price. The price of the stock seems to be hurting from the general downturn in the NASDAQ. The products are competively priced and well received by dermatologists. The president was receptive to answering questions and his response to the dilution question was "If the stock price is below 16.5 it is not worth issueing additional stock because of warrants cashing in" I don't know to much about warrants so I can't comment on his response. I would suggest that you request the investors package it has a great deal of information on the products and the analysts expectations.

Jane
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext